ARTICLE | Company News
Merck ends AD deal with Acumen
December 22, 2011 1:21 AM UTC
Acumen Pharmaceuticals Inc. (Livermore, Calif.) said Merck & Co. Inc. (NYSE:MRK) terminated a 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to Acumen, Merck made the decision based on "internal strategic priorities." Acumen said the program is in preclinical testing. ...